Spike Protein News and Research

RSS

SARS-CoV-2 spike protein recognized by innate immune receptors in a glycan-dependent way

The spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) depends on its ability to infect new host cells following its replication and release from infected cells. This pivots on its ability to bind to cell surface receptors like the ACE2 enzyme.

3 Aug 2020

New bivalent vaccine delivers robust cell-mediated and humoral immunity against SARS-CoV-2

In a groundbreaking bioRxiv study, US researchers demonstrate the capability of next-generation bivalent human adenovirus serotype 5 (hAd5) vaccine for inducing both cellular and humoral immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – using both an S protein sequence optimized for cell surface expression and a conserved nucleocapsid antigen designed to be transported to the endosomal subcellular compartment.

2 Aug 2020

COVID-19 rapid antibody test receives CE mark and mass production begins

The COVID-19 rapid antibody test, developed by Abingdon Health, the medical device manufacturer leading the UK-Rapid Test Consortium, has received its CE mark. This means it is approved for professional use in the UK and EU.

31 Jul 2020

War of sugars - estrogen provides protection in COVID-19

Now a new study published on the preprint server bioRxiv in July 2020 reports that sex hormones could affect the function of the fusion protein that is dependent upon the human ACE2 receptor, thus preventing the entry of the virus into the host cell.

31 Jul 2020

Researcher uses in silico analysis of SARS-CoV-2 spike protein to fast-track passive immunity

With millions of COVID-19 cases reported across the globe, people are turning to antibody tests to find out whether they have been exposed to the coronavirus that causes the disease. But what are antibodies? Why are they important? If we have them, are we immune to COVID-19? And if not, why not?

30 Jul 2020

Novel vaccine candidate robustly protects non-human primates against SARS-CoV-2

The development of a safe and effective vaccine will likely be required to end the COVID-19 pandemic. A group of scientists, led by Beth Israel Deaconess Medical Center immunologist Dan H. Barouch, MD, PhD, now report that a leading candidate COVID-19 vaccine developed at BIDMC in collaboration with Johnson & Johnson raised neutralizing antibodies and robustly protected non-human primates against SARS-CoV-2, the virus that causes COVID-19.

30 Jul 2020

New test rapidly determines neutralizing antibodies against Sars-Cov-2

To determine immunity to Sars-Cov-2 and the effectiveness of potential vaccines, the amount of neutralizing antibodies in the blood of recovered or vaccinated individuals must be determined.

30 Jul 2020

Relatives of SARS-CoV-2 may pose a health threat for years to come

Coronaviruses are zoonotic viruses that jump from animals to humans and cause infection. There are many types of common human coronaviruses, which usually cause mild to moderate upper-respiratory tract illnesses, like the common cold. Most people get infected with one or more of coronavirus types 229E, NL63, OC43, and HKU1 at some point in their lives.

29 Jul 2020

Iota-carrageenan from red seaweed inhibits SARS-CoV-2 in laboratory conditions

In a recent bioRxiv paper, a research group from the Marinomed Biotech biopharmaceutical company in Austria showed that a sulfated polysaccharide iota-carrageenan has the propensity to inhibit cell entry of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by using an in vitro neutralization assay.

29 Jul 2020

SARS-CoV-2 exposure five times more likely among Black and Hispanic pregnant women

Black and Hispanic pregnant women in Philadelphia are five times as likely as white and Asian women to have been exposed to the novel coronavirus, according to a new study led by Scott Hensley, PhD, an associate professor of Microbiology in the Perelman School of Medicine at the University of Pennsylvania, and Karen Marie Puopolo, MD, PhD, an associate professor of Pediatrics and neonatologist at the Children's Hospital of Philadelphia. The study was published today in Science Immunology.

29 Jul 2020

Study explores if prior exposure to common cold viruses may affect SARS-CoV-2 severity

A study led by Charité - Universitätsmedizin Berlin and the Max Planck Institute for Molecular Genetics (MPIMG) shows that some healthy individuals possess immune cells capable of recognizing the novel coronavirus, SARS-CoV-2.

29 Jul 2020

Inconsistent SARS-CoV-2 antibody results in nephrology workers

Using a broad spectrum of antibody tests the present study revealed inconsistent results for SARS-CoV-2 seroprevalence among asymptomatic individuals, while this was not the case among Covid-19 patients.

29 Jul 2020

Exciting cost-effective SARS-CoV-2 vaccine candidate using Newcastle disease

Experts warn that the world may see repeated waves of the COVID-19 pandemic. However, scientists around the world are working hard to create a protective vaccine or antiviral, which could help to reduce the number of deaths and cases the next time around.

29 Jul 2020

Basigin/CD147 discarded as an accessory SARS-CoV-2 binding receptor

By using specialized assays customized to detect specific receptor interactions, researchers from the Wellcome Sanger Institute in Cambridge UK find no evidence for direct binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein to a transmembrane glycoprotein known as basigin.

28 Jul 2020

Emergent SARS-CoV-2 D614G spike mutation more infective due to "open" morphology

Researchers from the Los Alamos National Laboratory and Duke Human Vaccine Institute & Department of Surgery demonstrated that globally prevalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with the amino acid substitution D614G in the spike protein is much more infective due to profitable binding encounters with the host receptors.

28 Jul 2020

Experimental vaccine rapidly controls coronavirus in the upper and lower airways of nonhuman primates

Two doses of an experimental vaccine to prevent coronavirus disease 2019 (COVID-19) induced robust immune responses and rapidly controlled the coronavirus in the upper and lower airways of rhesus macaques exposed to SARS-CoV-2, report scientists from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. SARS-CoV-2 is the virus that causes COVID-19.

28 Jul 2020

Evolutionary origins of SARS-CoV-2 identified

By reconstructing the evolutionary history of SARS-CoV-2, the virus that is responsible for the COVID-19 pandemic, an international research team of Chinese, European and U.S. scientists has discovered that the lineage that gave rise to the virus has been circulating in bats for decades and likely includes other viruses with the ability to infect humans.

28 Jul 2020

Scientists develop COVID-19 test to detect neutralizing antibodies with high sensitivity, specificity

According to a study published in Nature Biotechnology, the sVNT is capable of detecting the functional neutralizing antibodies (NAbs) that can block the binding of the coronavirus spike protein to the angiotensin-converting enzyme 2 (ACE2) host receptor, which mimics the virus-host interaction.

25 Jul 2020

Seaweed extract outperforms remdesivir in inhibiting SARS-CoV-2 in cell studies

In a test of antiviral effectiveness against the virus that causes COVID-19, an extract from edible seaweeds substantially outperformed remdesivir, the current standard antiviral used to combat the disease.

24 Jul 2020

An important SARS-CoV-2 enzyme is responsible for low in vivo antiviral efficacy of hydroxychloroquine

Researchers have shown that hydroxychloroquine interferes with only one redundant pathway that activates the SARS-CoV-2 spike protein.

24 Jul 2020

Spike Protein News and Research

SARS-CoV-2 spike protein recognized by innate immune receptors in a glycan-dependent way

New bivalent vaccine delivers robust cell-mediated and humoral immunity against SARS-CoV-2

COVID-19 rapid antibody test receives CE mark and mass production begins

War of sugars - estrogen provides protection in COVID-19

Researcher uses in silico analysis of SARS-CoV-2 spike protein to fast-track passive immunity

Novel vaccine candidate robustly protects non-human primates against SARS-CoV-2

New test rapidly determines neutralizing antibodies against Sars-Cov-2

Relatives of SARS-CoV-2 may pose a health threat for years to come

Iota-carrageenan from red seaweed inhibits SARS-CoV-2 in laboratory conditions

SARS-CoV-2 exposure five times more likely among Black and Hispanic pregnant women

Study explores if prior exposure to common cold viruses may affect SARS-CoV-2 severity

Inconsistent SARS-CoV-2 antibody results in nephrology workers

Exciting cost-effective SARS-CoV-2 vaccine candidate using Newcastle disease

Basigin/CD147 discarded as an accessory SARS-CoV-2 binding receptor

Emergent SARS-CoV-2 D614G spike mutation more infective due to "open" morphology

Experimental vaccine rapidly controls coronavirus in the upper and lower airways of nonhuman primates

Evolutionary origins of SARS-CoV-2 identified

Scientists develop COVID-19 test to detect neutralizing antibodies with high sensitivity, specificity

Seaweed extract outperforms remdesivir in inhibiting SARS-CoV-2 in cell studies

An important SARS-CoV-2 enzyme is responsible for low in vivo antiviral efficacy of hydroxychloroquine

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News